Idaho latest to sue Lilly because of Zyprexa
Pharma Compliance Alert, September 10, 2008
Add Idaho to the growing list of states to sue Eli Lilly for the way it marketed its antipsychotic drug Zyprexa.
The state accused Lilly of marketing Zyprexa for off-label uses and downplayed side effects, according to an Idaho Statesman article. Lilly denies the allegations and said it warned about the drug potentially causing diabetes and weight gain, so Idaho officials should not have been surprised by the side effects.
In April, Lilly agreed to pay the state of Alaska $15 million to end a trial to determine whether the company improperly marketed Zyprexa. At least nine other states have lawsuits pending against Lilly and the company asked that the Idaho lawsuit be moved to New York and consolidated with other state lawsuits.
Lilly is also in talks with the federal government to resolve allegations it improperly marketed Zyprexa and hid the side effects.
Comments
0 comments on “Idaho latest to sue Lilly because of Zyprexa ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Healthcare Marketing Advisor
Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...
-
Marketing Oncology: Strategies for Service Line Campaigns
During this 90-minute Webcast, expert healthcare marketers discuss the research and strategic planning that should be the...
-
The Complete Guide to Hospital Marketing, Second Edition
The Complete Guide to Hospital Marketing, Second Edition looks at the complex field of healthcare marketing in a...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- New FAQ posted on storing laryngoscope blades
- Q/A: Coding for telescopic intraocular lens
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Searched